Cisplatin-resistant derivatives of murine L1210 leukemia cells are not susceptible to growth-inhibiting and apoptosis-inducing actions of transforming growth factor-β1

Anti-Cancer Drugs

Volumn 10, Issue 5, 1999, Pages 457-463

  Stoika, R S ^a   Yakymovych, M Ya ^a   Yakymovych, I A ^a   Chekhun, V F ^a  

^a INSTITUTE OF HYDROBIOLOGY   (Ukraine)

Author keywords

Cisplatin; Growth inhibition; L1210 leukemia cells; Resistance; Transforming growth factor 1

Indexed keywords

CISPLATIN; DNA; TRANSFORMING GROWTH FACTOR BETA1; ANTINEOPLASTIC METAL COMPLEX;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CELL COUNT; COLONY FORMATION; CONTROLLED STUDY; DNA SYNTHESIS; DRUG RESISTANCE; LEUKEMIA L 1210; MOUSE; NONHUMAN; PRIORITY JOURNAL; CELL GROWTH; GROWTH INHIBITION;

EID: 0033457379     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199906000-00005     Document Type: Article

References (22)

1. Gately DP, Howell SB. Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer 1993; 67: 1171-6.
2. Chu G. Cellular responses to cisplatin. Cancer 1994; 269: 787-90.
3. Massague J. TGF-β signal transduction. Annu Rev Biochem 1998; 67: 753-91.
4. Derynk R, Feng XH. TGF-β receptor signaling. Biochim Biophys Acta 1997; 1333: F105-50.
5. Hurta RAR, Samual SK, Greenberg AH, Wroght JA. Early induction of ribonucleotide reductase gene expression by transforming growtli factor β1 in malignant Ha-ras transformed cell lines. J Biol Chem 1991; 266: 24097-100.
6. de Cotean JF, Kuans PI, Yankelev H, et al. Loss of functional cell surface transforming growth factor beta (TGF-beta) type I receptor correlates with insensitivity to TGF-beta in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1997; 94: 5877-81.
7. Raynal S, Nocentini S, Croisy A, Lawrence DA, Julien P. Transforming growth factor-beta 1 enhances the lethal effects of DNA-damaging agents in a human lung-cancer cell line. Int J Cancer 1997; 72: 356-61.
8. Maccarone M, Nieuwenkuizen WE, Dulens HF, et al. Membrane modification in human eruthroleukemia K562 cells during induction of programmed cell death by transforming growth factor beta 1 or cisplatin. Eur J Biochem 1996; 241: 297-302.
9. McCornack SE, Bruskin AM, Borzillo GV. A p53 growth arrest protects fibroblasts from anticancer agents. BioSci 1997; 1: A37-45.
10. Motyl T, Kasterka M, Grzelkowska K, et al. Phorbol ester (12-O-tetradecanoyl phorbol 13-acetate) prevents ornithine decarboxylase inhibition and apoptosis in L1210 leukemic cells exposed to TGF-beta 1. Int J Biochem Cell Biol 1996; 28: 1327-35.
11. Waud WR. Differential uptake of cis-diaminedichloroplatinum (II) by sensitive and resistant murine L1210 leukemia cells. Cancer Res 1987; 47: 6549-55.
12. Rizzino A. Soft agar growth assays for transforming growth factors and mitogenic peptides. In: Barnes D, Sirbasku DA, eds. Methods in enzymology. New York: Academic Press 1987: 341-52.
13. Herrmann M, Lorenz HM, Voll R, Grunke M, Woith W, Kalden JR. A rapid and simple method for the isolation of apoptotic DNA fragments. Nucleic Acid Res 1994; 22: 5506-7.
14. Segal-Bendirdjian E, Jacquemin-Sablon A. Cisplatin resistance in a murine leukemia cell line is associated with a defective apoptotic process. Exp Cell Res 1995; 218: 201-12.
15. Kraker AJ, Moore CW. Accumulation of cis-diaminedichloroplatinum (II) and platinum. Cancer Res 1988; 48: 9-13.
16. Kawai K, Kamavatani N, Georges E, Ling V. Identification of a membrane glycoprotein overexpressed in murine lymphoma sublines resistant to cis-diaminedichloroplatinum (II). J Biol Chem 1990; 265: 13137-42.
17. Stasyk TV, Antonyuk VA, Yakymovych MYa, et al. A comparative study of cell surface glycosyl determinants in sensitive and resistant to cisplatin L1210 murine leukemia cells. Exp Oncol 1998; 20: 204-9.
18. Sheibani N, Jennerwein MM, Eastman A. DNA repair in cells sensitive and resistant to cis-diaminedichloroplatinum(II); host cell reactivation of damaged plasmid DNA. Biochemistry 1998; 28: 3120-5.
19. Hettinga JVE, Lemstra W, Meijer C, et al. Mechanism of hyperthermic potentiation of cisplatin action in cisplatin-sensitive and -resistant human tumour cells. Br J Cancer 1997; 75: 1735-43.
20. Hronas RA, Andrew PA, Murphy MP, Burns CP. Glutathione depletion reverses cisplatin resistance in murine L1210 leukemia cells. Cancer Lett 1987; 34: 9-15.
21. Haak-Frendscho M, Wynn TA, Czuprynski CJ, Pattlnock D. Transforming growth factor-beta 1 inhibits activation of macrophage cell line RAW 264.7 for cell killing. Clin Exp Immunol 1990; 82: 404-10.
22. Barrack ER. TGF beta in prostate cancer: a growth inhibitor that can enhance tumorigenecity. Prostate 1997; 31: 61-70.